Palvella Therapeutics (PVLA) Cash from Operations Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.13% |
| Dec 31, 2025 | 18.18% |
| Sep 30, 2025 | -0.81% |
| Jun 30, 2025 | 11.09% |
| Mar 31, 2025 | 14.86% |
| Dec 31, 2024 | 17.34% |
| Sep 30, 2024 | 26.35% |
| Jun 30, 2024 | 31.63% |
| Mar 31, 2024 | 40.76% |
| Dec 31, 2023 | 33.61% |
| Sep 30, 2023 | 7.50% |
| Jun 30, 2023 | -8.37% |
| Mar 31, 2023 | -18.64% |
| Dec 31, 2022 | -22.47% |
| Sep 30, 2022 | -17.60% |
| Jun 30, 2022 | -19.02% |
| Mar 31, 2022 | -23.55% |
| Dec 31, 2021 | -10.22% |
| Sep 30, 2021 | -32.29% |
| Jun 30, 2021 | 47.13% |
| Mar 31, 2021 | -51.53% |
| Dec 31, 2020 | -40.03% |
| Sep 30, 2020 | -16.44% |
| Jun 30, 2020 | -25.96% |
| Mar 31, 2020 | -33.32% |
| Sep 30, 2019 | -290.59% |
| Jun 30, 2019 | -25.80% |
| Mar 31, 2019 | -104.88% |
| Dec 31, 2018 | -525.24% |
| Sep 30, 2018 | -401.82% |
| Jun 30, 2018 | -700.17% |